Authors
Poroshina M.A., Pedanova E.K.
The S.N. Fyodorov National Medical Research Center «MNTK «Eye Microsurgery», Moscow
Abstract
A clinical case of the development of macular neovascularization against the background of focal chorioretinitis of unknown etiology in the cicatricial stage. The patient was treated with anti-VEGF which is the “gold standard” for the treatment of retinal neovascularization.
Keywords: case report, chorioretinitis, angiography, neovascularization, anti-VEGF therapy.
References
1. Stokkermans TJ, Havens SJ. Toxoplasma Retinochoroiditis. 2022 Jun 21. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
2. Jester JV, Smith RE. Subretinal neovascularization after experimental ocular histoplasmosis in a subhuman primate. Am J Ophthalmol. 1985 Aug 15;100(2):252-8. doi: 10.1016/0002-9394(85)90790-1.
3. Martín García E, Chávarri García JJ, Rodríguez Vicente L, Jiménez Del Río B, Guallar Leza SM, Del Río Mayor JL. Management of the neovascular choroidal membrane secondary to ocular toxoplasmosis. Arch Soc Esp Oftalmol (Engl Ed). 2020 Feb;95(2):90-93. English, Spanish. doi: 10.1016/j.oftal.2019.11.003. Epub 2019 Dec 23.
4. Zito R, Micelli Ferrari T, Di Pilato L, Lorusso M, Ferretta A, Micelli Ferrari L, Accorinti M. Clinical course of choroidal neovascular membrane in West Nile virus chorioretinitis: a case report. J Med Case Rep. 2021 Apr 19; 15(1):206. doi: 10.1186/s13256-021-02700-0.
5. Giuffrè C, Marchese A, Cicinelli MV, Miserocchi E, Querques G, Bandello F, Modorati G. Multimodal imaging and treatment of syphilitic choroidal neovascularization. Retin Cases Brief Rep. 2022 Jan 1;16(1):85-88. doi: 10.1097/ICB.0000000000000912.
6. Jampol LM, Sung J, Walker JD, Folk JC, Townsend-Pico WA, Lowder CY, Dodds EM, Westrich D, Terry J. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am J Ophthalmol. 1996 Jun;121(6):643-9. doi: 10.1016/s0002-9394(14)70630-0.
7. Khandwala NS, Hyde RA, Besirli CG. Toxoplasma Retinochoroiditis with Chorioretinal Neovascularization in a Young Patient. Case Rep Ophthalmol. 2021 Apr 16;12(1):259-263. doi: 10.1159/000512286.
8. Ho CPS, Lai TYY. Pharmacotherapy for Choroidal Neovascularization Due to Uncommon Causes. Curr Pharm Des. 2018;24(41):4882-4895. doi: 10.2174/1381612825666190206105943.
9. Pérez de Arcelus M, Salinas A, García Layana A. Manifestaciones retinianas de las enfermedades infecciosas [Retinal manifestations of infectious diseases]. An Sist Sanit Navar. 2008;31 Suppl 3:57-68. Spanish.
10. Makragiannis G, Vahdani K, Carreño E, Lee RWJ, Dick AD, Ross AH. Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. Int Ophthalmol. 2018 Apr;38(2):781-785. doi: 10.1007/s10792-017-0502-x. Epub 2017 Mar 30.
11. Zhang YK, Fu HY, Guan Y, Li YJ, Bai HZ. Concurrent tuberculous chorioretinitis with choroidal neovascularization and tuberculous meningitis: a case report. BMC Ophthalmol. 2020 Jun 12;20(1):227. doi: 10.1186/s12886-020-01504-y.
12. Battaglia Parodi M, Iacono P, Verbraak FD, Bandello F. Antivascular endothelial growth factors for inflammatory chorioretinal disorders. Dev Ophthalmol. 2010;46:84-95. doi: 10.1159/000320011. Epub 2010 Aug 10.
13. Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG; Minerva study group. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the Minerva Study. Retina. 2018 Aug;38(8):1464-1477. doi: 10.1097/IAE.0000000000001744.
